Subscribe to Newsletter

Looking into the crystal ball: predicting the aggregation propensity of antibodies

Fully automated analysis of antibody formulations using chemical and thermal denaturation

One of the most important parameters in the development of therapeutic biologics is their long-term stability. Despite appearing stable in various formulations once purified, many antibodies display very slow aggregation kinetics over time. Thus far, this gradual aggregation could only be evaluated by monitoring monomer and aggregate content over months, or even years. Predictive methods for monitoring aggregation would address this urgent technology gap and help speed up the development timeline of biologics.

Read the full article now

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE!

Login
Receive content, products, events as well as relevant industry updates from The Analytical Scientist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Analytical Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine

Register